Pancreatic Cancer Research

Clinical trialPhase 2Terminated

FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer

Phase II Single Arm Clinical Trial of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer

Outcome
Stopped early. Results posted; single-arm, no comparisonResults unlikely to impact treatment patterns. Time to complete not justified. (Other)
Phase
Phase 2
Status
Terminated
Study type
Interventional
Start
January 2012
Ended
22 November 2016
Enrollment
9 participants
Sites
1
Primary outcomes
Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer
Sponsor type
Academic / other
Results posted
21 August 2017
Last update
6 October 2017

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 6 October 2017
OS
Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic CancerFOLFIRINOX: 28.5 (6.2 to NA), n = 5 (Insufficient number of participants with events)Values: median months, 95% Confidence IntervalTime frame: Up to 3 yearsNo analysis posted for this outcome (outcome 1)
Participants
FOLFIRINOX: 9 started, 9 completed
Serious adverse events
FOLFIRINOX: 2 of 9Participants with at least one serious adverse event, of those at risk, as posted
5 secondary outcomes
OS · Overall Survival for Borderline Resectable Patients
FOLFIRINOX 9.0 (5.8 to 16.2), n=4 [median Months, 95% Confidence Interval]
PFS · Progression Free Survival (PFS)
FOLFIRINOX 10.7 (2.0 to 24.8), n=9 [median Months, 95% Confidence Interval]
ORR · Objective Response Rate
FOLFIRINOX 11 (0 to 48), n=9 [percentage of patients, 95% Confidence Interval]
DCR · Disease Control Rate (DCR)
FOLFIRINOX 89 (52 to 100), n=9 [percentage of patients, 95% Confidence Interval]
Rate of Resectability (RR)
FOLFIRINOX 22 (0 to 60), n=9 [percentage of patients, 95% Confidence Interval]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

FOLFIRINOX regimen was recently presented at an international oncology meeting and represents a new standard in the treatment of metastatic pancreatic cancer for selected patients. With improved overall survival (OS) and response rates (RR) in the metastatic setting, we hypothesize that in patients with less tumor burden, this regimen will be safe and well tolerated, improve OS, progression free survival (PFS), and RR, and improve resectability rates, as compared to historical data from standard single agent gemcitabine therapy for unresectable locally advanced (ULA) patients and standard radiation with concurrent 5 fluorouracil (5FU) chemotherapy for borderline resectable (BR) patients. While both ULA and BR patients will be eligible for the present study, our primary objective concerns ULA patients, and we plan to enroll 45 patients in this group. Patients meeting eligibility criteria will be consented and treated with FOLFIRINOX every 2 weeks (1 cycle = 4 weeks = 2 treatments). Patients will undergo repeat imaging (CT or MRI) every 2 cycles and reassessed for resectability of the tumor. All patients that are not able to undergo surgical resection, due to insufficient down-staging or patient preference, will continue on protocol-based therapy until disease progression, unacceptable toxicity, study withdrawal, or death.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer [Up to 3 years]. Median, months (95% Confidence Interval). FOLFIRINOX (n=5): 28.5 (6.2 to NA) [Insufficient number of participants with events].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival for Borderline Resectable Patients [Up to 3 years]. Median, Months (95% Confidence Interval). FOLFIRINOX (n=4): 9.0 (5.8 to 16.2).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression Free Survival (PFS) [the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years]. Median, Months (95% Confidence Interval). FOLFIRINOX (n=9): 10.7 (2.0 to 24.8).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Objective Response Rate [Up to 3 years]. Number, percentage of patients (95% Confidence Interval). FOLFIRINOX (n=9): 11 (0 to 48).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Disease Control Rate (DCR) [Up to 3 years]. Number, percentage of patients (95% Confidence Interval). FOLFIRINOX (n=9): 89 (52 to 100).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Rate of Resectability (RR) [Up to 3 years]. Number, percentage of patients (95% Confidence Interval). FOLFIRINOX (n=9): 22 (0 to 60).